EMBL and Life Sciences Partners sell Luxendo to Bruker

Bruker will expand its existing portfolio of swept-field confocal, super-resolution, and multiphoton fluorescence microscope product lines with the addition of Luxendo's microscopes and intellectual property.

Bruker has previously made acquisitions in this field, acquiring US-based Vutara in 2014. Vutara specialised in 3D, super-resolution fluorescence microscopy. Luxendo will join Bruker’s Nano Group division, into which Vutara was also integrated.

Previous funding
EMBL and LSP invested in a €6m series-A funding round for Luxendo in October 2015. Both investors then backed a €2m extension of this funding round in January 2017. 

Company
Founded in 2015 and based in Heidelberg, Luxendo is a spinout from the European Molecular Biology Laboratory (EMBL). Single-plane illumination microscopes combine optical sectioning with multiple-view imaging to observe tissues and living organisms in high resolution.

It launched its two patented microscopes, Muvi-spim and Invi-spim in 2016, which allow scientists to observe living organisms without the risk of photodamage.

People
EMBL Venture Capital Partners – Stefan Herr (managing director).
Life Science Partners – Joachim Rothe (partner).
Bruker – Mark Munch (president).
Luxendo – Andreas Pfuhl (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• DACH
• Healthcare
• Germany
• Trade sale
• Life Science Partners